INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Ventyx Biosciences, Inc. (NASDAQ: VTYX) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

Company Overview - Ventyx Biosciences develops oral therapies targeting autoimmune, inflammatory, and neurodegenerative diseases [3] Allegations of Wrongdoing - Edelson Lechtzin LLP is investigating Ventyx for potential violations of federal securities laws due to allegations of misleading business information [1] - On December 2, 2025, Ventyx announced a delay in the Phase 2 trial of VTX2735 for recurrent pericarditis, with topline results now expected in Q1 2026. This delay is attributed to testing a new once-daily formulation and expanding the study into Canada, the EU, and the UK [4] - Following the announcement, Ventyx's stock price dropped by $1.44 per share, or 15.35%, closing at $7.94 per share on the same day [4]